Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.67 |
| ▸ | EGFR | P00533 | 4/20 | 0.60 |
| ▸ | ITK | Q08881 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15252565 | 0.84 | SYK (0.61) | SYKEGFRITKAURKAKDR | |
| SCHEMBL12519555 | 0.83 | SYK (0.65) | SYKEGFRITKAURKA | |
| SCHEMBL18594603 | 0.83 | SYK (0.62) | SYKEGFRITKAURKAKDR | |
| SCHEMBL655928 | 0.82 | SYK (0.69) | SYKEGFRAURKA | |
| SCHEMBL655523 | 0.82 | SYK (1.00) | SYKITKAURKAKDR | |
| SCHEMBL18720121 | 0.81 | SYK (0.61) | SYKEGFRITKAURKA | |
| SCHEMBL10229037 | 0.79 | SYK (0.72) | SYKEGFRAURKA | |
| SCHEMBL20927086 | 0.77 | EGFR (0.82) | SYKEGFRITKAURKA | |
| SCHEMBL656609 | 0.76 | SYK (0.70) | SYKEGFRAURKAKDR | |
| SCHEMBL657783 | 0.76 | ULK1 (0.69) | SYKEGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | SYK 610/4885EGFR 460/4885ITK 317/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885EGFR 1981/4885ITK 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.